Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

Bristol-Myers Squibb (BMS)

Status and phase: Active, not recruiting; Phase 3

Conditions: Psoriasis

Treatments: Drug: BMS-986165

Study type: Interventional

Funder types: Industry

Identifiers

NCT04036435

2019-000612-29 (Registry Identifier)

IM011-075

Details and patient eligibility

About

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Enrollment: 1,452 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
• Women must not be pregnant, lactating, or breastfeeding

Exclusion criteria

• Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
• To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,452 participants in 1 patient group

BMS-986165

Experimental group

Treatment:

Drug: BMS-986165